Date | Price Target | Rating | Analyst |
---|---|---|---|
1/25/2024 | $26.00 | Outperform | Oppenheimer |
1/8/2024 | Overweight | Cantor Fitzgerald | |
12/18/2023 | $29.00 | Outperform | Raymond James |
11/10/2023 | $18.00 → $26.00 | Hold → Buy | Jefferies |
8/16/2023 | $27.00 | Buy | Guggenheim |
1/4/2023 | $32.00 → $6.00 | Buy → Hold | Jefferies |
1/4/2023 | $33.00 → $8.00 | Outperform → Neutral | Wedbush |
7/12/2022 | $35.00 | Overweight | JP Morgan |
BRISBANE, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it will host an in-person and virtual R&D Day in New York, NY at 8:00 AM ET on Wednesday, October 2, 2024. To register, click here. The event will feature Jonathan Barratt, MD, PhD, FRCP (University of Leicester), Richard Lafayette, MD, FACP (Stanford University Medical Center), and Brad Rovin, MD (Ohio State University Wexner Medical Center), who will join the company's management team to discuss Vera's expanded ataci
On track to announce topline results from ORIGIN 3 trial in Q2 2025Expect to present 96-week data from ORIGIN Phase 2b clinical trial of atacicept in IgAN in Q4 2024 BRISBANE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed enrollment ahead of schedule for the primary endpoint in the pivotal Phase 3 ORIGIN 3 trial of atacicept in patients with IgAN. The enrollment of 200 participants in this initial cohort of the trial will provide data for the 36-week UPCR
BRISBANE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on September 5, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 21,750 shares of Class A common stock and restricted stock units (RSUs) for 9,875 shares of Class A common stock to two new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option granted on September 5, 2024 has an exercise price per share equal to $38.16, Vera's closing trading price on September
10-Q - Vera Therapeutics, Inc. (0001831828) (Filer)
8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
Oppenheimer initiated coverage of Vera Therapeutics with a rating of Outperform and set a new price target of $26.00
Cantor Fitzgerald initiated coverage of Vera Therapeutics with a rating of Overweight
Raymond James initiated coverage of Vera Therapeutics with a rating of Outperform and set a new price target of $29.00
BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of David L. Johnson as Chief Operating Officer, effective immediately. "We are excited to have David join our executive team at this important time for our clinical program of atacicept for the treatment of IgAN. We expect long-term 96-week data from the Phase 2b ORIGIN trial later this year and primary endpoint results from our pivotal Phase 3 clinical trial in the first half of 2025, and we look forward to
BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to its board of directors, effective June 7, 2024. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, including being recognized for building highly effective teams and leading significant commercial product launches. "We are delighted to welcome Christy to our Board during this important period in Vera's history. Her extensive experience and counsel will be
BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the appointments of two industry veterans to help lead the development of the company's drug programs including its late-stage product candidate, atacicept, to treat autoimmune diseases, currently in a Phase 3 clinical trial for IgA nephropathy (IgAN). The company has appointed Robert M. Brenner, M.D., as Chief Medical Officer to succeed Dr. Celia Lin, M.D.; and William D. Turner as Chief Development Officer, effective immediately. "We
SC 13D/A - Vera Therapeutics, Inc. (0001831828) (Subject)
SC 13D/A - Vera Therapeutics, Inc. (0001831828) (Subject)
SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday. Shares of Stericycle, Inc. (NASDAQ:SRCL) rose sharply during Monday's session after the company inked a deal to be acquired by Waste Management Inc. (NYSE:WM) for approximately $7.2 billion, including debt. Stericycle shares climbed 15% to $59.28 on Monday. Here are some other big stocks recording gains in today’s session. GameStop Corp. (NYSE:GME) shares jumped 34.5% to $31.13 after Roaring Kitty on a Reddit post, shared his position on the stock. MarineMax, Inc. (NYSE:HZO) jumped 27% to $36.16. OneWater Marine Inc. is reportedly said to be in advanced discussions to acquire MarineMax. L
The U.S. stock market ended a five-week positive streak as investors feared that slowing economic momentum could impact the earnings outlook for American corporations. The U.S. economy grew at an annualized rate of 1.3% in the first quarter, marking a downward revision from the previous estimate of 1.6%. The Fed's preferred inflation measure remained steady in April, easing some worries about resuming price pressures. Yet, slowing spending and income growth also signaled weakening consumer health, while the Chicago business activity gauge plummeted to its lowest level since May 2020, raising concerns about a potential end-cycle slowdown. The tech sector, as tracked by the Technology
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of eGFR versus placebo in this high-risk population Atacicept was well tolerated with safety profile similar to placebo Positive results support atacicept 150 mg as a potential disease-modifying treatment for patients with IgA nephropathy; Phase 3 (ORIGIN 3) clinical trial initiated in June 2023 Conference call and webcast to take place on June 20th, 2023, at 8:00 a.m. ET to further discuss results BRISBANE, Calif., June 17, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a la
Vera continuing plans to rapidly advance atacicept into a pivotal Phase 3 trial in 1H 2023; full data to be presented at upcoming medical congresses Company plans to prioritize and focus current resources on the advancement of atacicept in IgA Nephropathy into a pivotal Phase 3 trial, extending cash runway to Q4 2024 Conference call and webcast to take place on January 30th at 8:00am ET BRISBANE, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced results from a prespecified per-protocol (PP)
Atacicept met primary endpoint at 24 weeks, and also achieved statistical significance in the 150 mg dose group with a 33% mean reduction in proteinuria from baseline, with available data showing trend towards further reductions in proteinuria at week 36 Atacicept safety profile in IgAN patients was similar to placebo Vera plans to advance atacicept into a pivotal Phase 3 trial in the first half of 2023 Company to host investor conference call and webcast on January 4, 2023, at 8:00 a.m. ET to further discuss results BRISBANE, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing